Literature DB >> 28869782

Olmutinib-induced palmoplantar keratoderma.

K L Chen1,2, Y T Cho1, C W Yang1, Y S Sheen1, C W Liang3, M E Lacouture4, C Y Chu1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28869782      PMCID: PMC5812798          DOI: 10.1111/bjd.15935

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  8 in total

1.  Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma.

Authors:  Brandi M Kenner-Bell; Amy S Paller; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2010-08       Impact factor: 11.527

2.  Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.

Authors:  Kai-Lung Chen; Chia-Chi Lin; Yung-Tsu Cho; Che-Wen Yang; Yi-Shuan Sheen; Hsiao-En Tsai; Chia-Yu Chu
Journal:  JAMA Dermatol       Date:  2016-03       Impact factor: 10.282

3.  Olmutinib: First Global Approval.

Authors:  Esther S Kim
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

Review 4.  The hand-foot-syndrome associated with medical tumor therapy - classification and management.

Authors:  Annette Degen; Mareike Alter; Florian Schenck; Imke Satzger; Bernward Völker; Alexander Kapp; Ralf Gutzmer
Journal:  J Dtsch Dermatol Ges       Date:  2010-05-06       Impact factor: 5.584

5.  A gain-of-function mutation in TRPV3 causes focal palmoplantar keratoderma in a Chinese family.

Authors:  Yuqing He; Kang Zeng; Xibao Zhang; Qiaolin Chen; Jiang Wu; Hong Li; Yong Zhou; Gustavo Glusman; Jared Roach; Alton Etheridge; Shizhen Qing; Qiang Tian; Inyoul Lee; Xin Tian; Xiaoning Wang; Zhihua Wu; Leroy Hood; Yuanlin Ding; Kai Wang
Journal:  J Invest Dermatol       Date:  2014-10-06       Impact factor: 8.551

Review 6.  Acquired palmoplantar keratoderma.

Authors:  Shaily Patel; Matthew Zirwas; Joseph C English
Journal:  Am J Clin Dermatol       Date:  2007       Impact factor: 7.403

7.  Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma.

Authors:  Elizabeth Pohler; Ons Mamai; Jennifer Hirst; Mozheh Zamiri; Helen Horn; Toshifumi Nomura; Alan D Irvine; Benvon Moran; Neil J Wilson; Frances J D Smith; Christabelle S M Goh; Aileen Sandilands; Christian Cole; Geoffrey J Barton; Alan T Evans; Hiroshi Shimizu; Masashi Akiyama; Mitsuhiro Suehiro; Izumi Konohana; Mohammad Shboul; Sebastien Teissier; Lobna Boussofara; Mohamed Denguezli; Ali Saad; Moez Gribaa; Patricia J Dopping-Hepenstal; John A McGrath; Sara J Brown; David R Goudie; Bruno Reversade; Colin S Munro; W H Irwin McLean
Journal:  Nat Genet       Date:  2012-10-14       Impact factor: 38.330

8.  iRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function.

Authors:  Matthew A Brooke; Sarah L Etheridge; Nihal Kaplan; Charlotte Simpson; Edel A O'Toole; Akemi Ishida-Yamamoto; Olivier Marches; Spiro Getsios; David P Kelsell
Journal:  Hum Mol Genet       Date:  2014-03-18       Impact factor: 6.150

  8 in total
  3 in total

1.  Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety.

Authors:  Xiaohan Hu; Sheng Tang; Feiyi Yang; Pengwu Zheng; Shan Xu; Qingshan Pan; Wufu Zhu
Journal:  Molecules       Date:  2021-05-20       Impact factor: 4.411

Review 2.  Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.

Authors:  Shang-Gin Wu; Jin-Yuan Shih
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

3.  Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells.

Authors:  Jiansheng Zhong; Jinli Zhang; Xiaoyang Yu; Xing Zhang; Linping Dian
Journal:  Med Sci Monit       Date:  2020-08-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.